Apoptosis and restriction of G1/S cell cycle by fenretinide in Burkitt's lymphoma Mutu I cell line accessed with bcl-6 down-regulation

Biochemical and Biophysical Research Communications

Volumn 276, Issue 3, 2000, Pages 1295-1301

  Hsieh, Tze chen ^a   Wu, Joseph M ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENRETINIDE; PROTEIN BCL 6; RETINOIC ACID; RETINOID;

APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CANCER CELL CULTURE; CANCER PREVENTION; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PHOSPHORYLATION; PRIORITY JOURNAL;

EID: 0034610009     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2000.3617     Document Type: Article

References (56)

1. Preventive and enhancing effects of retinoids on the development of naturally occurring tumors of skin, prostate gland, and endocrine pancreas in aged male ACI/segHapBR rats
2. Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide
3. Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras + myc-induced carcinomas in the mouse prostate reconstitution model system
4. Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma
5. Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer
6. Phase II study of the retinoid analogue 4-HPR in men with carcinoma of the prostate
7. Mammographic patterns in breast cancer chemoprevention with fenretinide (4-HPR)
8. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck
9. Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate
10. Chemoprevention of breast cancer with fenretinide (4-HPR): Data from benign and malignant breast tissue and plasma 4-HPR kinetics
11. Fenretinide-induced apoptosis in human head and neck squamous carcinoma cell lines
12. Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines
13. N-(4-Hydroxyphenyl) retinamide is cytotoxic to melanoma cells in vitro through the induction of programmed cell death
14. Effects of fenretinide (4-HPR) on prostate LNCaP cell growth, apoptosis, and prostate-specific gene expression
15. Combined effect of chemopreventative agent N-(4-hydroxyphenyl) retinamide (4-HPR) and gamma-radiation on bladder cancer cell lines
16. Differential effects of N-(4-hydroxyphenyl) retinamide and retinoic acid on neuroblastoma cells: Apoptosis versus differentiation
17. Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2
18. Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids: Implication for chemoprevention
19. Different Epstein-Barr Virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line
20. Bcl-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor
21. Induction of apoptosis and down-regulation of bcl-6 in Mutu I cells treated with ethanolic extracts of the Chinese herbal supplement PC-SPES
22. Bcl-6 gene hypermutations in diffuse large B-cell lymphoma of primary gastric origin
23. Small deletions occur in highly conserved regions of the LAZ 3/bcl-6 major translocation cluster in one case of non-Hodgkin's lymphoma without 3q27 translocation
24. Bcl-6 expression in reactive follicular hyperplasia, follicular lymphoma and angioimmunoblastic T-cell lymphoma with hyperplastic germinal centers: Heterogeneity of intrafollicular T-cells and their altered distribution in the pathogenesis of angioimmunoblastic T-cell lymphoma
25. Distribution and pattern of bcl-6 mutations throughout the spectrum of B-cell neoplasia
26. Mutation analysis of the 5' noncoding regulatory region of the bcl-6 gene in non-Hodgkin lymphoma: Evidence for recurrent mutations and intraclonal heterogeneity
27. The bcl-6 gene is predominantly expressed in keratinocytes at their termination differentiation stage
28. Expression of the bcl-6 gene in the pre- and postnatal mouse
29. Increased expression of the LAZ3(bcl-6) proto-onccgene accompanies murine skeletal myogenesis
30. The proto-oncogene bcl-6 inhibits apoptotic cell death in differentiation-induced mouse myogenic cells
31. The role of bcl-6 in mature cardiac myocytes
32. Bcl-6 expression during B-cell activation
33. Bcl-6 proteins is expressed in germinal-center B cells
34. Disruption of the bcl-6 gene results in an impaired germinal center formation
35. Mutation of bcl-6 gene in normal B cells by the process of somatic hypermutation of Ig genes
36. Control of inflammation, cytokine expression, and germinal center formation by bcl-6
37. Differential regulation of germinal center genes, bcl-6 and SWAP-70, during the course of MAIDS
38. The LAZ3/bcl-6 oncogene encodes a sequence-specific transcriptional inhibitor: A novel function for the BTB/POZ domain as an autonomous repressing domain
39. The LAZ3 (bcl-6) oncogene recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression
40. Transcriptional repression of Stat6-dependent interleukin-4-induced genes by bcl-6: Specific regulation of iepsilon transcription and immunoglobulin E switching
41. A lenovirus-mediated high expression of bcl-6 in CV-1 cells induces apoptotic cell death accompanied by down-regulation of bcl-2 and bcl-xL
42. Overexpressed bcl-6 (LAZ3) oncoprotein triggers apoptosis, delays S phase progression and associates with replication foci
43. 3 in androgen-dependent LNCaP cells
44. Cellular changes and induction of apoptosis in human promyelocytic HL-60 cells infected with the agent of human granulocytic ehrlichiosis (HGE)
45. 1/S transition and induction of apoptosis in HL-60 leukemia cells by fenretinide (4HPR)
46. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle
47. Transcriptional repression of the E2-containing promoters EIIaE, c-myc, and RB1 by the product of the RB1 gene
48. N-(4-Hydroxyphenyl)retinamide-induced death in human lymphoblastoid cells: 50 kb DNA breakage as a means of distinguishing apoptosis from necrosis
49. Neuroblastoma cell apoptosis induced by the synthetic retinoid N-(4-hydroxyphenyl)retinamide
50. Retinoic acid induces changes in c-fgr proto-oncogene mRNA levels in Burkitt's lymphoma cells
51. Retinoid-mediated inhibition of cell growth with stimulation of apoptosis in aggressive B-cell lymphomas
52. Growth modulation of freshly isolated non-Hodgkin's B-lymphoma cells induced by various cytokines and all-trans retinoic acid
53. Retinoic acid induces persistent, RARalpha-mediated anti-proliferative responses in Epstein-Barr virus-immortalized b lymphoblasts carrying an activated c-myc oncogene but not in Burkitt's lymphoma cell lines
54. N-(4-Hydroxyphenyl) retinamide induces cell cycle specific growth inhibition in PC3 cells
55. Effects of fenretinide (4-HPR) on prostate LNCaP cell growth, apoptosis, and prostate-specific gene expression
56. Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl) retinamide